Shelley Orwick

19PUBLICATIONS
91CO-AUTHORS
Epigenetics (incl. genome methylation and epigenomics)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Aug 25, 2026
Epigenetic markers expand genetic risk estimation in acute myeloid leukemia.

|Mar 02, 2026
Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability.

Nadeen Anabtawi, Thomas Drabison, Alexander F Ham

|Sep 19, 2025
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology).

Monica Cusan, Karilyn Larkin, Deedra Nicolet

|Aug 22, 2025
Drug-Drug Interaction Liabilities with BTK Inhibitor TL-895.

Jack C Stromatt, Eman A Ahmed, Thomas Drabison

|Jun 25, 2025
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.

Eric D Eisenmann, Ronan Swords, Ying Huang

|Jan 13, 2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies.

Nadeen Anabtawi, Deedra Nicolet, Najla Alotaibi

Pageof 4

Frequent Collaborators

13 joint publications

James S Blachly

8 joint publications

Krzysztof Mrózek

7 joint publications

Alice S Mims

6 joint publications

Sharyn D Baker